Follow
Mark C Evans
Mark C Evans
Associate Director, Bioinformatics and Technology Development, XOMA Corp.
Verified email at xoma.com
Title
Cited by
Cited by
Year
The Inducible G Protein-coupled Receptor edg-1 Signals via the Gi/Mitogen-activated Protein Kinase Pathway (∗)
MJ Lee, M Evans, T Hla
Journal of Biological Chemistry 271 (19), 11272-11279, 1996
2131996
Hypoxia promotes liver-stage malaria infection in primary human hepatocytes in vitro
S Ng, S March, A Galstian, K Hanson, T Carvalho, MM Mota, SN Bhatia
Disease models & mechanisms 7 (2), 215-224, 2014
80*2014
A highly virulent variant of HIV-1 circulating in the Netherlands
C Wymant, D Bezemer, F Blanquart, L Ferretti, A Gall, M Hall, T Golubchik, ...
Science 375 (6580), 540-545, 2022
552022
Recent advances in immunoinformatics: application of in silico tools to drug development
MC Evans
CURRENT OPINION IN DRUG DISCOVERY AND DEVELOPMENT 11 (2), 233, 2008
242008
Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
MC Evans, P Phung, AC Paquet, A Parikh, CJ Petropoulos, T Wrin, ...
BMC bioinformatics 15, 1-15, 2014
202014
Impact of HIV-1 reverse transcriptase E138 mutations on rilpivirine drug susceptibility
M Haddad, LA Napolitano, AC Paquet, MD Evans, CJ Petropoulos, ...
Antivir Ther 16 (Suppl 1), A18, 2011
202011
Molecular, cellular, and clinical aspects of angiogenesis
ME Maragoudakis
Springer Science & Business Media, 2012
13*2012
Mutation Y188L of HIV-1 reverse transciptase is strongly associated with reduced susceptibility to rilpivirine
M Haddad, L Napolitano, A Paquet, M Evans, C Petropoulos, J Whitcomb, ...
19th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 5-8, 2012
102012
The immediate-early gene product MAD-3/EDG-3/IκBα is an endogenous modulator of fibroblast growth factor-1 (FGF-1) dependent human endothelial cell growth
T Hla, AB Zimrin, M Evans, K Ballas, T Maciag
FEBS letters 414 (2), 419-424, 1997
81997
Methods and Systems for Identification of a Protein Binding Site
M Evans, M Haddad
US Patent App. 13/869,857, 2013
72013
A case-based reasoning system for genotypic prediction of hiv-1 co-receptor tropism
MC Evans, AC Paquet, W Huang, L Napolitano, A Frantzell, J Toma, ...
Journal of bioinformatics and computational biology 11 (04), 1350006, 2013
62013
Significant Reductions in the Prevalence of Protease Inhibitor and 3-Class Resistance: Recent Trends in a Large HIV-1 Protease/Reverse Transcriptase Database
A Paquet, MC Evans, C Petropoulos, J Whitcomb, E Coakley, ...
51st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2011
52011
Genome wide expression profiling of human peripheral blood mononuclear cells stimulated with BAY 50-4798, a novel T cell selective interleukin-2 analog
S Steppan, K Kupfer, A Mayer, M Evans, G Yamasaki, JM Greve, ...
Journal of Immunotherapy 30 (2), 150-168, 2007
42007
Cross-sectional Assessment of Telaprevir and Boceprevir Resistance-associated Mutations of 500 Clinical Samples Submitted for HCV NS3/4A Protease Inhibitor Drug Resistance …
JM Volpe, SS Choe, JD Reeves, W Huang, MC Evans, M Haddad, ...
Hepatology 56, 1007A, 2012
32012
Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
MC Evans, A Paquet, P Phung, A Parikh, C Petropoulos, T Wrin, ...
AIDS Vaccine 2012, 2012
2012
Novel vomputational methods for predicting
MC Evans, A Paquet, P Phung, A Parikh, C Petropoulos, T Wrin, ...
2012
The effect of incorporating a contrastive teaching approach on the learning of English in Brunei
SCS Ong, M Evans, A Yiakoumetti
ICERI2011 Proceedings, 2400-2400, 2011
2011
HIV-1 Polymerase Gene Polymorphisms are Associated with Phenotypic Differences in Replication Capacity and Disease Progression
OT Ng, O Laeyendecker, AD Redd, S Munshaw, MK Grabowski, ...
Genotypic Algorithm for Predicting Elvitegravir Susceptibility: Clinical Validation and Correlation with Phenotype
M Haddad, W Huang, MD Miller, K White, AC Paquet, MC Evans
The system can't perform the operation now. Try again later.
Articles 1–19